Pulmonary hypertension (PH) in left heart disease (LHD) is a challenge for cardiologists: in a setting of left ventricular dysfunction, the coexistence of PH and right ventricular dysfunction is known to be associated with very poor prognosis and limited efficacy of conventional medical treatments. This might explain why the off-label use of drugs specific for pulmonary arterial hypertension is quite diffuse in clinical practice in PH-LHD, despite randomized clinical trials do not provide evidence of their efficacy in such patients.
Pulmonary hypertension in left heart disease. the need to continue to explore / Ghio, S.; D'Alto, M.; Badagliacca, R.; Vizza, C. D.. - In: INTERNATIONAL JOURNAL OF CARDIOLOGY. - ISSN 0167-5273. - 288:(2019), pp. 132-134. [10.1016/j.ijcard.2019.03.027]
Pulmonary hypertension in left heart disease. the need to continue to explore
Badagliacca R.;Vizza C. D.
2019
Abstract
Pulmonary hypertension (PH) in left heart disease (LHD) is a challenge for cardiologists: in a setting of left ventricular dysfunction, the coexistence of PH and right ventricular dysfunction is known to be associated with very poor prognosis and limited efficacy of conventional medical treatments. This might explain why the off-label use of drugs specific for pulmonary arterial hypertension is quite diffuse in clinical practice in PH-LHD, despite randomized clinical trials do not provide evidence of their efficacy in such patients.File | Dimensione | Formato | |
---|---|---|---|
Ghio_Pulmonary_2019.pdf
accesso aperto
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Creative commons
Dimensione
488.05 kB
Formato
Adobe PDF
|
488.05 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.